Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc. (NASDAQ:TBPH) in an all-cash transaction valued at about $929 million.
The deal, which aims to bolster Zymeworks’ commercial portfolio, will pay $17 per share for Theravance Biopharma shares. The companies expect the deal to close in the second half of 2026.
Acquisition Adds YUPELRI To Zymeworks Portfolio
The acquisition will add Yupelri, the only approved once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease.
Zymeworks will gain access to a 35% share of U.S. net profits from Yupelri.
